Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639167 | 0.88 | ALDH1A1 (0.43) | ALDH1A1POLBKMT2AGAARAB9A | |
| SCHEMBL5638120 | 0.84 | ALDH1A1 (0.38) | ALDH1A1POLBFAAHKMT2AALOX15 | |
| SCHEMBL5637037 | 0.82 | KMT2A (0.49) | ALDH1A1KMT2AGAACYP1A2MAPT | |
| SCHEMBL5639413 | 0.79 | SCN9A (0.39) | POLBKMT2AGAAMAPTRAB9A | |
| SCHEMBL5640869 | 0.79 | NAAA (0.39) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL5638512 | 0.75 | THRB (0.43) | ALDH1A1POLBKMT2AGAACYP2D6 | |
| SCHEMBL5639328 | 0.74 | HPGD (0.37) | ALDH1A1POLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL5638355 | 0.74 | NPC1 (0.49) | ALDH1A1KMT2AALOX15GAACYP1A2 | |
| SCHEMBL5636422 | 0.74 | NAAA (0.33) | — | |
| SCHEMBL5638425 | 0.74 | KMT2A (0.43) | ALDH1A1KMT2AGAARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | ALDH1A1 1286/4885POLB 2325/4885FAAH 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.